Search Within

Malin Lisa Hultcrantz

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (73)
  2. Journal Article (20)
  3. Research Letter (4)
  4. Correspondence (2)
Groups
  1. Biostatistics Service (99)
  2. Center for Hematologic Malignancies (99)
  3. Department of Medicine (99)
  4. Epidemiology and Biostatistics (99)
  5. Hematologic Malignancies, Division of (99)
  6. Myeloma (99)

More Groups

People
  1. Alexander Lesokhin (90)
  2. Sham Mailankody (89)
  3. Hani Hassoun (87)
  4. Neha Korde (86)
  5. Urvi Shah (84)
  6. Carlyn Rose Tan (78)

More People

Years
  1. 2025 (2)
  2. 2024 (15)
  3. 2023 (24)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (11)

More Years

Publications
  1. Blood (41)
  2. Clinical Lymphoma, Myeloma and Leukemia (24)
  3. Journal of Clinical Oncology (8)
  4. Blood Cancer Journal (5)
  5. American Journal of Hematology (2)
  6. Blood Cancer Discovery (2)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. Elsevier Inc. (26)
  3. American Society of Clinical Oncology (8)
  4. Nature Publishing Group (7)
  5. American Association for Cancer Research (4)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (99)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Meeting Abstract

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Korde, N.; Lendvai, N.; Hassoun, H.; Lesokhin, A. M.; Lahoud, O. B.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
    Journal Article

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Chen, D.; Devlin, S. M.; more...
    PLoS ONE (2019)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Depth of response and outcomes in patients with multiple myeloma undergoing autologous stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Seier, K.; Devlin, S. M.; Chung, D. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; Lendvai, N.; Lesokhin, A. M.; Mailankody, S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • V(D)J sequence capture for DNA-based minimal residual disease detection in multiple myeloma
    Meeting Abstract

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Devlin, S. M.; Jacobsen, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Treatment outcomes in monoclonal immunoglobulin deposition disease (MIDD): A two center experience
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Flynn, J.; Devlin, S. M.; Jaffer-Sathick, I.; Rossi, A. C.; Salvatore, S. P.; Landau, H. J.; Lendvai, N.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
    Blood (2017)

    Fulltext@MSK | Save